XXŘ&Xxxxxx;XXX&Xxxxxx; XXXXXX (EU) č. 618/2012
ze xxx 10. čxxxxxxx 2012,
xxxx&xxxxxx;x xx xxx &xxxxxx;čxxx xřxxxůxxxxx&xxxxxx; xěxxxxx-xxxxxxxx&xxxxxx;xx xxxxxxx xěx&xxxxxx; xxř&xxxxxx;xxx&xxxxxx; Xxxxxxx&xxxxxx;xx xxxxxxxxxx a Xxxx (XX) č. 1272/2008 x klasifikaci, xxxxčxx&xxxxxx;x&xxxxxx; x xxxxx&xxxxxx; látek x směsí
(Xxxx s x&xxxxxx;xxxxxx pro XXX)
XXXXXXX&Xxxxxx; XXXXXX,
x&xxxx;xxxxxxx xx Xxxxxxx x&xxxx;xxxxxx&xxxxxx;x&xxxxxx; Xxxxxxx&xxxxxx; unie,
s ohledem xx xxř&xxxxxx;xxx&xxxxxx; Evropského xxxxxxxxxx x&xxxx;Xxxx (XX) č.&xxxx;1272/2008 ze xxx 16.&xxxx;xxxxxxxx 2008 x&xxxx;xxxxxxxxxxx, xxxxčxx&xxxxxx;x&xxxxxx; a balení x&xxxxxx;xxx x&xxxx;xxěx&xxxxxx;, o změně a zrušení xxěxxxx 67/548/XXX x&xxxx;1999/45/XX x&xxxx;x&xxxx;xxěxě xxř&xxxxxx;xxx&xxxxxx; (XX) č.&xxxx;1907/2006 (1), x&xxxx;xxxx&xxxxxx;xx xx čx.&xxxx;37 odst. 5 xxxxxx&xxxxxx;xx xxř&xxxxxx;xxx&xxxxxx;,
xxxxxxxx x&xxxx;xěxxx xůxxxůx:
(1) |
Č&xxxxxx;xx 3 xř&xxxxxx;xxxx XX xxř&xxxxxx;xxx&xxxxxx; (XX) č.&xxxx;1272/2008 xxxxxxxx xxx xxxxxxx xxxxxxxxxxxx&xxxxxx;xx xxxxxxxxxx&xxxxxx; x&xxxx;xxxxčxx&xxxxxx; nebezpečných x&xxxxxx;xxx. X&xxxx;xxxxxxx 3.1 je xxxxxx seznam xxxxxxxxxxxx&xxxxxx;xx xxxxxxxxxx&xxxxxx; a označení xxxxxxxčx&xxxxxx;xx x&xxxxxx;xxx xx x&xxxxxx;xxxxě xxxx&xxxxxx;xx&xxxxxx; stanovených x&xxxx;č&xxxxxx;xxxxx 2 xž 5 xř&xxxxxx;xxxx X&xxxx;xxř&xxxxxx;xxx&xxxxxx; (ES) č.&xxxx;1272/2008. X&xxxx;xxxxxxx 3.2 xx uveden xxxxxx xxxxxxxxxxxx&xxxxxx;xx xxxxxxxxxx&xxxxxx; x xxxxčxx&xxxxxx; xxxxxxxčx&xxxxxx;xx látek xx x&xxxxxx;xxxxě xxxx&xxxxxx;xx&xxxxxx; xxxxxxxx&xxxxxx;xx v příloze XX xxěxxxxx Xxxx 67/548/EHS xx dne 27.&xxxx;čxxxxx 1967 x sbližování xx&xxxxxx;xx&xxxxxx;xx x správních xřxxxxxů x&xxxxxx;xxx&xxxxxx;x&xxxxxx;xx se xxxxxxxxxxx, balení a xxxxčxx&xxxxxx;x&xxxxxx; nebezpečných x&xxxxxx;xxx (2). Xxxx xxx xxxxxxx xx xxxx&xxxxxx; změnit, xxx xx xxxx xxxx zahrnuty aktualizované xxxxxxxxxxx x&xxxxxx;xxx, xx xxxx&xxxxxx; se již xxxxxxxx harmonizovaná klasifikace, x aby xxxxxxxxxx x xxx&xxxxxx; xxxxxxxxxxxx&xxxxxx; xxxxxxxxxxx. |
(2) |
X&xxxxxx;xxx xxx posuzování xxxxx Xxxxxxx&xxxxxx; xxxxxxxx xxx chemické x&xxxxxx;xxx (XXXX) vydal xxxxxxxxxx x x&xxxxxx;xxxůx xxxxxxxxxxxx&xxxxxx; xxxxxxxxxxx x xxxxčxx&xxxxxx;x&xxxxxx; x&xxxxxx;xxx, xxxx&xxxxxx; xxxx xřxxxxžxxx xxxxxxřx x xxxxxxx s čx&xxxxxx;xxxx 37 xxř&xxxxxx;xxx&xxxxxx; (XX) č. 1272/2008. Xx x&xxxxxx;xxxxě xěxxxx stanovisek x na x&xxxxxx;xxxxě xřxxxx&xxxxxx;xxx obdržených xx xxxčxx&xxxxxx;xx xxxxx je xřxxx xxěxxx xř&xxxxxx;xxxx XX xxř&xxxxxx;xxx&xxxxxx; (XX) č. 1272/2008, xxx xxxx xxxxžxxx xxxxxxxxxxx xxxxxxxxxxx x xxxxčxx&xxxxxx;x&xxxxxx; xěxxxx&xxxxxx;xx x&xxxxxx;xxx. |
(3) |
Xxxxxxxxxxxx&xxxxxx; xxxxxxxxxxx xxxxxxxx&xxxxxx; x&xxxx;č&xxxxxx;xxx 3 xř&xxxxxx;xxxx VI xxř&xxxxxx;xxx&xxxxxx; (XX) č.&xxxx;1272/2008, ve xxěx&xxxxxx; tohoto xxř&xxxxxx;xxx&xxxxxx;, xx xx neměly xxxž&xxxxxx;x xxxxxxxxřxxxě, neboť xxxxxx&xxxxxx;řxx&xxxxxx; subjekty budou xxxřxxxxxx určité období xx xx, aby xxxxx novým klasifikacím xřxxxůxxxxx xxxxčxx&xxxxxx;x&xxxxxx; a balení x&xxxxxx;xxx x&xxxx;xxěx&xxxxxx; a xxxxxx xxxxxxx&xxxxxx;x&xxxxxx; x&xxxxxx;xxxx. Xxxxxx&xxxxxx;řxx&xxxxxx; subjekty xxxxx xxxxě xxxx xxxřxxxxxx xxčxx&xxxxxx; časové xxxxx&xxxxxx; xx xx, xxx xxxxx xxxxxx xxxxxxxxxx xxx xxxxxxxxxx, xxxx&xxxxxx; xxxx&xxxxxx;xxx&xxxxxx; x&xxxx;xxx&xxxxxx;xx xxxxxxxxxxxx&xxxxxx;xx xxxxxxxxxx&xxxxxx; x&xxxxxx;xxx klasifikovaných xxxx karcinogenní, xxxxxxxx&xxxxxx; xxxx xxxxxx&xxxxxx; xxx xxxxxxxxxx, xxxxxxxx&xxxxxx; 1X x&xxxx;1X (tabulka 3.1) x&xxxx;xxxxxxxx&xxxxxx; 1 x&xxxx;2 (xxxxxxx 3.2) xxxx xxxx xxxxxx toxické xxx xxxx&xxxxxx; xxxxxxxxx x&xxxx;xxžxxxx&xxxxxx; vyvolat xxxxxxxxx&xxxxxx; xxxř&xxxxxx;xxxx&xxxxxx; &xxxxxx;čxxxx xx xxxx&xxxxxx;x prostředí, xxxx&xxxxxx;xx xxx xxxxxxxxxx stanovené x&xxxx;čx&xxxxxx;xxx&xxxx;23 nařízení Evropského xxxxxxxxxx a Rady (ES) č.&xxxx;1907/2006 xx xxx 18.&xxxx;xxxxxxxx 2006 x&xxxx;xxxxxxxxxx, xxxxxxxx&xxxxxx;, povolování x&xxxx;xxxxxx&xxxxxx;x&xxxxxx; xxxxxxx&xxxxxx;xx x&xxxxxx;xxx, x&xxxx;xř&xxxxxx;xxx&xxxxxx; Xxxxxxx&xxxxxx; xxxxxxxx xxx xxxxxxx&xxxxxx; x&xxxxxx;xxx, x&xxxx;xxěxě xxěxxxxx 1999/45/ES x&xxxx;x&xxxx;xxx&xxxxxx;xx&xxxxxx; xxř&xxxxxx;xxx&xxxxxx; Xxxx (XXX) č.&xxxx;793/93, xxř&xxxxxx;xxx&xxxxxx; Xxxxxx (XX) č.&xxxx;1488/94, xxěxxxxx Xxxx 76/769/EHS x&xxxx;xxěxxxx Xxxxxx 91/155/XXX, 93/67/XXX, 93/105/XX x&xxxx;2000/21/XX (3). |
(4) |
V souladu x&xxxx;xřxxxxxx&xxxxxx;x xxxxxxxxx&xxxxxx;x xxř&xxxxxx;xxx&xxxxxx; (XX) č. 1272/2008, které xxxžňxxx užití xxx&xxxxxx;xx xxxxxxxxx&xxxxxx; x&xxxx;xřxxxxxxxx xx x&xxxxxx;xx dobrovolnosti, xx xěxx x&xxxxxx;x xxxxxxxxx&xxxxxx; xxžxxxx používat xxxxxxxxxxxxxx xxxxxxxxxxx stanovenou x&xxxx;č&xxxxxx;xxx 3 xř&xxxxxx;xxxx VI xxř&xxxxxx;xxx&xxxxxx; (XX) č. 1272/2008, ve znění xxxxxx nařízení, a xřxxxůxxxxx označování x xxxxx&xxxxxx; odpovídajícím xxůxxxxx xx xxxxxxxxx&xxxxxx; x&xxxxxx;xx xřxx 1. prosincem 2013. |
(5) |
Xxxxřxx&xxxxxx; xxxxxxxx&xxxxxx; x&xxxxxx;xxx xxř&xxxxxx;xxx&xxxxxx;x xxxx x&xxxx;xxxxxxx xx xxxxxxxxxxx x&xxxxxx;xxxx xř&xxxxxx;xxx&xxxxxx;xx xxxxx čx&xxxxxx;xxx 133 nařízení (XX) č.&xxxx;1907/2006, |
XŘXXXXX XXXX NAŘÍZENÍ:
Čx&xxxxxx;xxx&xxxx;1
Č&xxxxxx;xx 3 přílohy XX xxř&xxxxxx;xxx&xxxxxx; (ES) č.&xxxx;1272/2008 xx xěx&xxxxxx; xxxxx:
1) |
Xxxxxxx 3.1 xx xěx&xxxxxx; xxxxx:
|
2) |
Xxxxxxx 3.2 xx mění xxxxx:
|
Čx&xxxxxx;xxx&xxxx;2
Xxxx xxř&xxxxxx;xxx&xxxxxx; vstupuje x&xxxx;xxxxxxxx xxxx&xxxxxx;x&xxxxxx;x dnem xx vyhlášení x&xxxx;&Xxxxxx;řxxx&xxxxxx;x xěxxx&xxxxxx;xx Xxxxxxx&xxxxxx; unie.
Čx&xxxxxx;xxx 1 xx použije xxx dne 1. xxxxxxxx 2013.
Xxxxxxxxxxxx&xxxxxx; xxxxxxxxxxx xxxxxxxx&xxxxxx; v části 3 xř&xxxxxx;xxxx XX nařízení (XX) č.&xxxx;1272/2008, xx xxěx&xxxxxx; xxxxxx xxř&xxxxxx;xxx&xxxxxx;, xxx použít před 1.&xxxx;xxxxxxxxx 2013.
Xxxx xxř&xxxxxx;xxx&xxxxxx; je x&xxxxxx;xxxx&xxxxxx; x&xxxx;xxx&xxxxxx;x xxxxxxx x&xxxx;xř&xxxxxx;xx xxxžxxxxx&xxxxxx; xx x&xxxxxx;xxx čxxxxx&xxxxxx;xx xx&xxxxxx;xxxx.
X Xxxxxxx xxx 10. čxxxxxxx 2012.
Za Xxxxxx
Xxx&xxxxxx; Xxxxxx XXXXXXX
xřxxxxxx
(1)&xxxx;&xxxx;&Xxxxxx;ř.&xxxx;xěxx.&xxxx;X&xxxx;353, 31.12.2008, x.&xxxx;1.
(2)&xxxx;&xxxx;&Xxxxxx;ř. věst. 196, 16.8.1967, s. 1.
(3)&xxxx;&xxxx;&Xxxxxx;ř.&xxxx;xěxx.&xxxx;X&xxxx;136, 29.5.2007, x.&xxxx;3.
XŘ&Xxxxxx;XXXX&xxxx;X
Xxxxxxx&xxxxxx; č&xxxxxx;xxx |
Mezinárodní xxxxxxxxxxxx xxxxxxx&xxxxxx;xx x&xxxxxx;xxx |
Č&xxxxxx;xxx XX |
Č&xxxxxx;xxx XXX |
Xxxxxxxxxxx |
Xxxxčxx&xxxxxx; |
Xxxxxxxxx&xxxxxx; koncent. limity, xxxxxxxxxxčx&xxxxxx; faktory |
Xxxx. | |||
X&xxxxxx;xx xř&xxxxxx;x x xxxxxxxx&xxxxxx; xxxxxxxčxxxxx |
X&xxxxxx;xx xxxxxxxxx&xxxxxx;xx xěx x xxxxxxxčxxxxx |
X&xxxxxx;xx x&xxxxxx;xxxxžx&xxxxxx;xx xxxxxxů x xxxx&xxxxxx;xx&xxxxxx;xx xxxx |
X&xxxxxx;xx xxxxxxxxx&xxxxxx;xx xěx x xxxxxxxčxxxxx |
X&xxxxxx;xx doplň. xxxxxxxxx&xxxxxx;xx xěx x xxxxxxxčxxxxx | ||||||
„009-016-00-2 |
xxxxxxxxx xxxxxxxxxxxxxxxxxxx [1] |
237-410-6 [1] |
13775-53-6 [1] |
XXXX RE 1 Xxxxx Xxx. 4 Xxxxxxx Xxxxxxx 2 |
X372 X332 X411 |
XXX07 XXX08 XXX09 Xxx |
X372 X332 X411 |
&xxxx; |
&xxxx; |
&xxxx; |
xxxxxxxxx hexafluoroaluminate (xxxxxxxx) [2] |
239-148-8 [2] |
15096-52-3 [2] | ||||||||
603-012-00-X |
2-xxxxxxxxxxxxx; xxxxxxxx xxxxxx monoethyl xxxxx |
203-804-1 |
110-80-5 |
Xxxx. Xxx. 3 Xxxx. 1X Acute Xxx. 3 Acute Xxx. 4 |
X226 X360XX X331 X302 |
XXX02 XXX08 XXX06 Xxx |
X226 X360XX X331 X302 |
&xxxx; |
&xxxx; |
&xxxx; |
603-025-00-0 |
xxxxxxxxxxxxxxx |
203-726-8 |
109-99-9 |
Xxxx. Liq. 2 Xxxx. 2 Xxx Xxxxx. 2 XXXX XX 3 |
X225 H351 X319 X335 |
XXX02 XXX07 GHS08 Xxx |
X225 X351 X319 X335 |
XXX019 |
XXXX XX 3; X335: X ≥ 25&xxxx;% Xxx Xxxxx.2; X319: X &xx; 25 % |
&xxxx; |
613-016-00-3 |
xxxxxxxxxxxx (XXX); 2-(2-xxxxx)-1X-xxxxxxxxxxxxx |
223-404-0 |
3878-19-1 |
Xxxx. 2 Xxxxx Tox. 4 XXXX XX 2 Skin Sens. 1 Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1 |
H351 X302 X373 (xxxxx) X317 H400 X410 |
GHS07 XXX08 GHS09 Xxx |
X351 X302 X373 (xxxxx) X317 X410 |
&xxxx; |
X = 1 |
|
617-001-00-2 |
di-tert-butyl xxxxxxxx |
203-733-6 |
110-05-4 |
Xxx. Perox. E Xxxx. Xxx. 2 Muta. 2 |
H242 X225 X341 |
XXX02 XXX08 Dgr |
X242 H225 H341“ |
&xxxx; |
&xxxx; |
|
XŘ&Xxxxxx;XXXX&xxxx;XX
Xxxxxxx&xxxxxx; č&xxxxxx;xxx |
Xxxxx&xxxxxx;xxxx&xxxxxx; xxxxxxxxxxxx xxxxxxx&xxxxxx;xx látek |
Č&xxxxxx;xxx XX |
Číslo XXX |
Xxxxxxxxxxx |
Xxxxčxx&xxxxxx; |
Xxxxxxxxx&xxxxxx; koncent. xxxxxx, xxxxxxxxxxčx&xxxxxx; xxxxxxx |
Xxxx. | |||
Kódy xř&xxxxxx;x x xxxxxxxx&xxxxxx; nebezpečnosti |
X&xxxxxx;xx xxxxxxxxx&xxxxxx;xx vět x xxxxxxxčxxxxx |
X&xxxxxx;xx x&xxxxxx;xxxxžx&xxxxxx;xx symbolů x xxxx&xxxxxx;xx&xxxxxx;xx xxxx |
X&xxxxxx;xx xxxxxxxxx&xxxxxx;xx vět o xxxxxxxčxxxxx |
X&xxxxxx;xx xxxxň. standardních xěx o nebezpečnosti | ||||||
„015-199-00-X |
tris[2-chloro-1-chloromethyl)ethyl] xxxxxxxxx |
237-159-2 |
13674-87-8 |
Xxxx. 2 |
X351 |
XXX08 Xxx |
X351 |
|
&xxxx; |
&xxxx; |
015-200-00-3 |
xxxxxx xxxxxxxxx |
244-959-5 |
22398-80-7 |
Carc. 1X Xxxx. 2 XXXX RE 1 |
X350 X361x X372 (xx&xxxxxx;xx) |
GHS08 Xxx |
H350 X361x X372 (plíce) |
|
STOT XX 1; H372: X&xxxx;&xx;&xxxx;0,1&xxxx;% Xxxx 1X; X350: X&xxxx;&xx;&xxxx;0,01&xxxx;% XXXX RE 2; X373: 0,01&xxxx;%&xxxx;&xx; X&xxxx;&xx;&xxxx;0,1&xxxx;% |
&xxxx; |
015-201-00-9 |
trixylyl xxxxxxxxx |
246-677-8 |
25155-23-1 |
Xxxx. 1B |
X360X |
XXX08 Xxx |
X360X |
&xxxx; |
&xxxx; |
&xxxx; |
015-202-00-4 |
xxxx(xxxxxxxxxxx) xxxxxxxxx |
247-759-6 |
26523-78-4 |
Xxxx Xxxx. 1 Xxxxxxx Acute 1 Xxxxxxx Xxxxxxx 1 |
X317 X400 X410 |
GHS07 XXX09 Xxx |
H317 X410 |
&xxxx; |
&xxxx; |
&xxxx; |
015-203-00-X |
xxxxxxxx(2,4,6-xxxxxxxxxxxxxxxx)xxxxxxxxx xxxxx |
278-355-8 |
75980-60-8 |
Xxxx. 2 |
H361f (xxůxxxxxx xxxxxxx xxxxxx) |
GHS08 Wng |
X361x (způsobuje xxxxxxx xxxxxx) |
|
|
|
602-109-00-4 |
Hexabromocyclododecane [1] |
247-148-4 [1] |
25637-99-4[1] |
Xxxx. 2 Xxxx. |
X361 X362 |
XXX08 Xxx |
H361 X362 |
&xxxx; |
&xxxx; |
&xxxx; |
1,2,5,6,9,10-xxxxxxxxxxxxxxxxxxxxxx [2] |
221-695-9[2] |
3194-55-6[2] | ||||||||
606-143-00-0 |
xxxxxxxxx (xxxxxxxxxxx of xxxxxxxxxx X1x xxx xxxxxxxxxx X1x) (XXX) [1] |
_ [1] |
71751-41-2 [1] |
Xxxx. 2 Acute Xxx. 2 Acute Tox. 1 XXXX XX 1 Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1 |
X361x X300 X330 X372 (xxxxxx&xxxxxx; xxxx&xxxxxx;x) X400 X410 |
XXX06 XXX08 XXX09 Xxx |
X361x H300 H330 X372 (xxxxxx&xxxxxx; xxxx&xxxxxx;x) H410 |
&xxxx; |
STOT XX 1; X372: C ≥ 5 % XXXX XX 2; X373: 0,5&xxxx;%&xxxx;&xx; X&xxxx;&xx;&xxxx;5&xxxx;% M = 10 000 |
|
avermectin X1x (xxxxxx ≥ 80 %); [2] |
265-610-3 [2] |
65195-55-3 [2] | ||||||||
606-144-00-6 |
xxxxxxxxxxx (XXX); 3-xxxxxxx-1,4-xxxxx-1,4-xxxxxxxxxxxxxxxxx-2-xx xxxxxxx |
&xxxxx; |
57960-19-7 |
Xxxx Xxxx. 1 XXXX SE 1 STOT XX 2 Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1 |
X317 X370 (xx&xxxxxx;xx) (xxxxxxx&xxxxxx;x&xxxxxx;) X373 (krevní xxěx) X400 X410 |
XXX07 GHS08 GHS09 Dgr |
X317 X370 (xx&xxxxxx;xx) (xxxxxxx&xxxxxx;x&xxxxxx;) X373 (krevní xxěx) X410 |
&xxxx; |
X&xxxx;=&xxxx;1&xxxx;000 |
&xxxx; |
607-698-00-1 |
4-xxxx-xxxxxxxxxxxx xxxx |
202-696-3 |
98-73-7 |
Xxxx. 1X XXXX XX 1 Xxxxx Xxx. 4 |
X360X X372 X302 |
XXX07 XXX08 Dgr |
X360X X372 X302 |
&xxxx; |
&xxxx; |
&xxxx; |
612-281-00-2 |
xxxxxxxxxxxxxx xxxxx; X,X,X',X'-xxxxxxxxxxx-4,4'-xxxxxxxxxxxxxxxxxxxx |
204-961-9 |
129-73-7 |
Xxxx. 2 Xxxx. 2 |
H351 X341 |
XXX08 Xxx |
H351 H341 |
&xxxx; |
&xxxx; |
|
616-205-00-9 |
Xxxxxxxxxxx (XXX); 2-xxxxxx-X-(2,6-xxxxxxxxxxxxxx)-X-(1X-xxxxxxx-1-xxxxxxxx)xxxxxxxxx |
266-583-0 |
67129-08-2 |
Xxxx Xxxx. 1B Xxxx. 2 Xxxxxxx Acute 1 Aquatic Xxxxxxx 1 |
H317 X351 X400 X410 |
XXX07 XXX08 XXX09 Wng |
X317 X351 H410 |
&xxxx; |
M = 100 M = 100“ |
|
XŘ&Xxxxxx;XXXX&xxxx;XXX
Xxxxxxx&xxxxxx; č&xxxxxx;xxx |
Mezinárodní xxxxxxxxxxxx xxxxxxx&xxxxxx;xx x&xxxxxx;xxx |
Č&xxxxxx;xxx XX |
Č&xxxxxx;xxx XXX |
Xxxxxxxxxxx |
Xxxxčxx&xxxxxx; |
Xxxxxxxxxčx&xxxxxx; xxxxxx |
Xxxx. |
&xxxxx;009-016-00-2 |
xxxxxxxxx hexafluoroaluminate [1] |
237-410-6 [1] |
13775-53-6 [1] |
Xn; X20 X; R48/23/25 X; X51-53 |
X; X X: 20-48/23/25-51/53 X: (1/2-)22-37-45-61 |
&xxxx; |
|
trisodium xxxxxxxxxxxxxxxxxxx (cryolite) [2] |
239-148-8 [2] |
15096-52-3 [2] | |||||
603-012-00-X |
2-xxxxxxxxxxxxx; xxxxxxxx glycol xxxxxxxxx ether |
203-804-1 |
110-80-5 |
X10 Xxxx. Xxx. 2; R60-61 Xx; R20/22 |
X X: 60-61-10-20/22 X: 53-45 |
|
X |
603-025-00-0 |
xxxxxxxxxxxxxxx |
203-726-8 |
109-99-9 |
X; X11-19 Carc. Xxx. 3; X40 Xx; X36/37 |
X; Xn X: 11-19-40-36/37 S: (2-)(13-)16-29-33-36-37(-46) |
Xx; X36/37: C ≥ 25 % |
&xxxx; |
613-016-00-3 |
fuberidazole (XXX); 2-(2-xxxxx)-1X-xxxxxxxxxxxxx |
223-404-0 |
3878-19-1 |
Xxxx. Cat. 3; X40 Xx; X48/22 Xx; R22 Xx; X43 X; X50-53 |
Xn; X X: 40-48/22-22-43-50/53 X: (2)-22-36/37-60-61 |
X; X50-53: X&xxxx;&xx;&xxxx;25&xxxx;% X; R51-53: 2,5&xxxx;%&xxxx;&xx;&xxxx;X&xxxx;&xx;&xxxx;25&xxxx;% X52-53: 0,25&xxxx;%&xxxx;&xx;&xxxx;X&xxxx;&xx;&xxxx;2,5&xxxx;% |
&xxxx; |
617-001-00-2 |
xx-xxxx-xxxxx xxxxxxxx |
203-733-6 |
110-05-4 |
O; R7 X; X11 Xxxx. Xxx. 3, X68 |
X; F; Xx X: 7-11-68 X: (2-)3/7-14-16-23-36/37/39“ |
&xxxx; |
|
XŘ&Xxxxxx;XXXX&xxxx;XX
Xxxxxxx&xxxxxx; č&xxxxxx;xxx |
Xxxxx&xxxxxx;xxxx&xxxxxx; identifikace xxxxxxx&xxxxxx;xx x&xxxxxx;xxx |
Č&xxxxxx;xxx ES |
Č&xxxxxx;xxx XXX |
Xxxxxxxxxxx |
Xxxxčxx&xxxxxx; |
Xxxxxxxxxčx&xxxxxx; xxxxxx |
Xxxx. |
&xxxxx;015-199-00-X |
xxxx[2-xxxxxx-1-xxxxxxxxxxxx)xxxxx] phosphate |
237-159-2 |
13674-87-8 |
Xxxx. Xxx. 3; X40 |
Xx X: 40 X: (2-)36/37 |
&xxxx; |
|
015-200-00-3 |
xxxxxx xxxxxxxxx |
244-959-5 |
22398-80-7 |
Xxxx. Xxx. 2; X45 Xxxx. Xxx. 3; X62 T; X48/23 |
X X: 45&xxxxx;48/23&xxxxx;62 X: 45- 53 |
X; X48/23: X &xx;0,1% Xxxx Xxx 2; X45: X &xx; 0,01% Xx; X48/20: 0,01%&xx; X < 0,1% |
X |
015-201-00-9 |
xxxxxxxx xxxxxxxxx |
246-677-8 |
25155-23-1 |
Xxxx. Xxx. 2; X60 |
X X: 60 S: 53-45 |
&xxxx; |
&xxxx; |
015-202-00-4 |
tris(nonylphenyl) xxxxxxxxx |
247-759-6 |
26523-78-4 |
Xx; X43 X; X50-53 |
Xi; X X: 43-50/53 X: 24-37-60-61 |
&xxxx; |
&xxxx; |
015-203-00-X |
diphenyl(2,4,6-trimethylbenzoyl)phosphine xxxxx |
278-355-8 |
75980-60-8 |
Xxxx. Xxx. 3; X62 |
Xx X: 62 X: (2)-22-36/37. |
|
&xxxx; |
602-109-00-4 |
Xxxxxxxxxxxxxxxxxxxxxx [1] |
247-148-4 [1] |
25637-99-4[1] |
Xxxx. Xxx.&xxxx;3; X63 X64 |
Xx R: 63-64 X: 36/37-53 |
&xxxx; |
&xxxx; |
1,2,5,6,9,10-xxxxxxxxxxxxxxxxxxxxxx [2] |
221-695-9[2] |
3194-55-6[2] | |||||
606-143-00-0 |
abamectin (xxxxxxxxxxx xx xxxxxxxxxx B1a xxx avermectin X1x) (XXX) [1] |
_ [1] |
71751-41-2 [1] |
Xxxx. Xxx.&xxxx;3; X63 T+; X26/28 X; R48/23/25 X; X50-53 |
X+; X X: 63-26/28-48/23/25-50/53 X: 28-36/37-45-60-61 |
T; X48/23: X &xx; 5% Xx; R48/20: 0,5% &xx; C <5% X; X50-53: X ≥ 0,0025% X; X51-53: 0,00025% &xx; X &xx;0,0025% R52-53: 0,000025% &xx; X&xx;0,00025% |
&xxxx; |
avermectin X1x (purity ≥80%); [2] |
265-610-3 [2] |
65195-55-3 [2] | |||||
606-144-00-6 |
xxxxxxxxxxx (XXX); 3-xxxxxxx-1,4-xxxxx-1,4-xxxxxxxxxxxxxxxxx-2-xx xxxxxxx |
— |
57960-19-7 |
T; R39/23 Xx; X43 X; X50-53 |
X; N X: 39/23-43-50/53, X: (2-)24-37-38-60-61 |
N; X50-53: X &xx; 0,025% X; X51-53: 0,0025% &xx; X < 0,025% X52-53: 0,00025% &xx; X &xx; 0,0025% |
&xxxx; |
607-698-00-1 |
4-xxxx-xxxxxxxxxxxx xxxx |
202-696-3 |
98-73-7 |
Repr. Xxx. 2; X60 X; X48/23/24/25 Xx; X22 |
X R: 60-22-48/23/24/25 S: 53-45 |
&xxxx; |
X |
612-281-00-2 |
xxxxxxxxxxxxxx green X,X,X',X'-xxxxxxxxxxx-4,4'-xxxxxxxxxxxxxxxxxxxx |
204-961-9 |
129-73-7 |
Xxxx. Cat. 3;R40 Xxxx. Xxx. 3; X68 |
Xx R: 40-68 X: (2-)36/37 |
|
|
616-205-00-9 |
Metazachlor (XXX); 2-xxxxxx-X-(2,6-xxxxxxxxxxxxxx)-X-(1X-xxxxxxx-1-xxxxxxxx)xxxxxxxxx |
266-583-0 |
67129-08-2 |
X43 Xxxx. Xxx. 3; R40 X; X50-53 |
Xx; N R: 40-43-50/53 X: (2-)36-37-60-61 |
X; R50-53: X &xx; 0,25% N; R51-53: 0,025% &xx; C &xx; 0,25% R52-53: 0,0025% &xx; X &xx; 0,025%&xxxxx; |
&xxxx; |